Dive Into PrEP Data.
PrEP Clinical Trials
Prior to July 2012, there were three major clinical trials conducted that led to the eventual FDA approval of Truvada for use as HIV PrEP.
iPrEX
iPrEX had the objective to "determine whether daily oral TDF/FTC
(Truvada) can reduce the risk of HIV infection in men who have sex with men and
transgender who also receive HIV counseling, condoms, and treatment for other STIs."
Details of iPrEX Study:
- This study showed a high level of efficacy (92%) in study participants who took pills regularly but not as effective for study participants who were not adherent to treatment.
- There were 2,499 gay men, other men who have sex with men, and transgender women enrolled in the study.
- The study was conducted in six countries: Brazil, Ecuador, Peru, South Africa, Thailand, and the U.S.
- More info on iPrex:
TDF2
TDF2 "tested whether daily TDF/FTC (Truvada) was safe for HIV-negative sexually-active young
adults in Botswana and whether it reduced risk of HIV infection."
Details of the TDF2 Study:
- This study showed a high level of efficacy (78%) for study participants who were adherent to treatment but less efficacy for those who were not adherent.
- There were 1,219 HIV-negative heterosexual males and females enrolled in the study; the study was conducted in Botswana.
- More info on TDF2
Partners PrEP
Partners PrEP had the objective to "demonstrate if PrEP decreases HIV-1 acquisition among HIV uninfected
individuals within HIV-1 discordant couples." In other words, the study focused on couples where one partner
had HIV and the other one was HIV-negative.
Details of the Partners PrEP Study:
- Like the other two studies, this study showed a high level of efficacy (75%) when study participants stuck with the treatment regimine.
- There were 4,758 study participants, or 2,379 HIV serodiscordant couples.
- The study was conducted in various locations in Kenya and Uganda.
- More info on Partners PrEP